Post job

Ferring Pharmaceuticals CEO and executives

Executive Summary. Based on our data team's research, Sudheendra Kulkarni is the Ferring Pharmaceuticals's CEO. Ferring Pharmaceuticals has 6,500 employees, of which 28 are in a leadership position.
Here are further demographic highlights of the leadership team:
  • The Ferring Pharmaceuticals executive team is 36% female and 64% male.
  • 66% of the management team is White.
  • 9% of Ferring Pharmaceuticals management is Hispanic or Latino.
  • 10% of the management team is Black or African American.
Work at Ferring Pharmaceuticals?
Share your experience

Rate Ferring Pharmaceuticals' leadership communication with employees.

Zippia waving zebra
Name & TitleBio
Sudheendra Kulkarni

Chief Executive Officer - India & Neighbouring Countries

Sudheendra Kulkarni's LinkedIn

Country Manager enabling teams to deliver the present and charter the future aspirations, setting vision, strategising to capitalise on emerging opportunities in India and South Asian regions. P&L leader with multiple TA domain expertise, and across geographies in leading MNC,Indian companies with cultural diversity. Expertise in healthcare Sales& Marketing, Strategy, Business operations, new business venture management, strategic planning, managing acquisition, strategic alliance management, and International Business ( Includes Indian subcontinent of Srilanka, Bangladesh, Pakistan, Maldives etc), and exposure across AP markets.

Expertise in leading profitable growth at South west Asia cluster country level. specialty,chronic and mass base business units across leading MNC & Indian companies.Setting up of Key Account Management and international business.

Frederik Paulsen Sr

Chairman

Frederik Paulsen is a Swedish billionaire businessman and non-executive chairman of Ferring Pharmaceuticals.

Aaron Graff

Executive Vice President and Chief Commercial Officer

Aaron Graff joined Ferring in 2002 as Vice President Global Marketing, Business Development, and Medical Affairs, based in Copenhagen, Denmark. After leading the acquisition and integration of Israeli biopharmaceutical company BTG in 2005, he relocated his team to the newly established Ferring International Center in Saint-Prex, Switzerland, where he was promoted to Senior Vice President, Asia Region and Global Marketing. Since 2010, Graff has led Ferring’s U.S. operations from its U.S headquarters in New Jersey, first as Chief Operating Officer and since 2016 as Chief Executive Officer.

Prior to joining Ferring, Graff worked at Bristol-Myers Squibb for over 17 years in a variety of sales, marketing and commercial operations management positions

Armin Metzger

EVP & Chief Production Officer, Head of Global Technical Operations

Armin Metzger's LinkedIn

Armin joined Ferring from Merck Serono, where he worked for 17 years in Germany, the United States, Italy and Switzerland. He started as a Laboratory Manager, working in different leadership positions in Quality Control, Analytical Development, Project Management, Pharmaceutical and Process Development, as well as in Medical Device Development and finally holding a position as Senior Vice President, Head of Global Biotech Manufacturing and Development. Armin has a Ph.D. from the University of Bayreuth, Germany in Biochemistry followed by a Postdoc at the Medical Research Council, Laboratory of Molecular Biology, Cambridge, UK.

Curt McDaniel

Secretary To The Executive Committee and Chief Legal Officer

Curt McDaniel's LinkedIn

Curt joined Ferring in 2006 and is responsible for all Legal and Intellectual Property activities on a global basis. He has over 30 years of experience in the global pharmaceutical industry in various aspects of the business and in many different countries and cultures. He is also a writer of fiction and several of his short stories have been published.

Prior to joining Ferring, Curt worked at Eli Lilly and Company for over 16 years. He has a J.D. and an M.B.A. from Indiana University and B.A. from Purdue University.

Dominic Moorhead

Executive Vice President and Chief Financial Officer

Dominic Moorhead's LinkedIn

Dominic joined Ferring in July 2017 as Chief Financial Officer. He has been a strategic advisor to executives and investors in biotech.

Dominic has 30 years’ finance and business experience in the life sciences industry. Previously, he worked for Takeda Pharmaceuticals as Global Financial Controller, and CFO of the international business following the acquisition of Nycomed. Prior to this Dominic worked for Hoffmann-La Roche, where he was CFO of the Pharma Division for nine years during a period of transformation and growth. He was engaged in numerous strategic initiatives and business transactions, as well as their operational implications, culminating in the privatisation of Genentech in the U.S. in 2009.

Dominic has an ACA from Institute of Chartered Accountants in England and Wales and a BSc in Chemistry from the University of Nottingham.

Mirjam Mol-Arts

Executive Vice President and Chief Medical Officer

Mirjam Mol-Arts's LinkedIn

Mirjam Mol is a Chief Science Officer / Chief Medical Officer at Ferring Pharmaceuticals and is based in Eindhoven Area, Netherlands. She has worked as Raad van Toezicht at VPTZ Oss-Maasland; Sr VP and Franchise Head Women's Health & Endocrine at MERCK & CO., INC.; and Board Member at Radboudumc. Mirjam attended Utrecht University between 1980 and 1987.

Hélène Ploix

Chairman of The Audit and Finance Committee

Jeffrey D. Hobbs

Vice Chairman

Luzi von Bidder

Chairman of The Remuneration and Nomination Committee

Do you work at Ferring Pharmaceuticals?

Does the leadership team provide a clear direction for Ferring Pharmaceuticals?

Ferring Pharmaceuticals jobs

Ferring Pharmaceuticals board members

Name & TitleBio
Jean-Frédéric Paulsen

Board Member

Ferring Pharmaceuticals leadership demographics

Ferring Pharmaceuticals gender distribution in management team

  • The Ferring Pharmaceuticals executive team is 36% female and 64% male.
  • Ferring Pharmaceuticals is 52% female and 48% male company-wide.
Male
Male
64%
Company-wide: 48%
Female
Female
36%
Company-wide: 52%

Ferring Pharmaceuticals executives by race

Management Team:
  • The most common ethnicity among Ferring Pharmaceuticals executive officers is White.
  • 66% of the management team is White.
  • 11% of Ferring Pharmaceuticals's management is Asian.
  • 10% of the management team is Black or African American.
Company-wide:
  • White is the most common ethnicity company-wide.
  • 62% of employees are White.
  • 13% of employees are Hispanic or Latino.
  • 12% of employees are Black or African American.
  • Management team
  • General
100%
80%
60%
40%
20%
0%
Unknown
White
Black or African American
Asian
Hispanic or Latino

Ferring Pharmaceuticals jobs nearby

Ferring Pharmaceuticals executives FAQs

Zippia gives an in-depth look into the details of Ferring Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Ferring Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Ferring Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Ferring Pharmaceuticals. The data presented on this page does not represent the view of Ferring Pharmaceuticals and its employees or that of Zippia.

Ferring Pharmaceuticals may also be known as or be related to Ferring Pharmaceuticals, Ferring Pharmaceuticals Inc, Ferring Pharmaceuticals Inc. and Ferring Pharmaceuticals, Inc.